Cardioprotective Effects of a Novel Hydrogen Sulfide Agent-Controlled Release Formulation of S-Propargyl-Cysteine on Heart Failure Rats and Molecular Mechanisms

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Huang, Chengrong ^a   Kan, Juntao ^a   Liu, Xu ^b   Ma, Fenfen ^a   Tran, Hieu ^a   Zou, Yunzeng ^a   Wang, Shujun ^b   Zhu, Yi Zhun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; CYSTATHIONINE GAMMA LYASE; DIGOXIN; GLUTATHIONE; HYDROGEN SULFIDE; PROPAGYLGLYCINE; PROTEIN BAX; PROTEIN BCL 2; S PROPARGYLCYSTEINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR RESPONSE; CELL DAMAGE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; RAT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CYSTEINE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; FIBROSIS; HEART FAILURE; HEART VENTRICLES; HYDROGEN SULFIDE; MALE; OXIDATIVE STRESS; RATS;

RATTUS;

EID: 84879978507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069205     Document Type: Article

References (28)

1. Jessup M, Brozena S, (2003) Medical progress: Heart failure. N Engl J Med 348: 2007-2018.
2. Bui AL, Horwich TB, Fonarow GC, (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8: 30-41.
3. Cohn JN, (1996) Drug therapy- The management of chronic heart failure. N Engl J Med 335: 490-498.
4. Wang R, (2002) Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16: 1792-1798.
5. Abe K, Kimura H, (1996) The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071.
6. Lefer DJ, (2007) A new gaseous signaling molecule emerges: Cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci U S A 104: 17907-17908.
7. Zhao WM, Zhang J, Lu YJ, Wang R, (2001) The vasorelaxant effect of H2S as a novel endogenous gaseous K-ATP channel opener. EMBO J 20: 6008-6016.
8. Yang GD, Wu LY, Jiang B, Yang W, Qi JS, et al. (2008) H(2)S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587-590.
9. Wang YF, Zhao X, Jin HF, Wei HL, Li W, et al. (2009) Role of Hydrogen Sulfide in the Development of Atherosclerotic Lesions in Apolipoprotein E Knockout Mice. Arterioscler Thromb Vasc Biol 29: 173-U171.
10. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, et al. (2007) Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 104: 15560-15565.
11. Zhu YZ, Wang ZJ, Ho P, Loke YY, Zhu YC, et al. (2007) Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. J Appl Physiol 102: 261-268.
12. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, et al. (2010) Genetic and Pharmacologic Hydrogen Sulfide Therapy Attenuates Ischemia-Induced Heart Failure in Mice. Circulation 122: 11-U45.
13. Wang Q, Wang XL, Liu HR, Rose P, Zhu YZ, (2010) Protective Effects of Cysteine Analogues on Acute Myocardial Ischemia: Novel Modulators of Endogenous H2S Production. Antioxid Redox Signal 12: 1155-1165.
14. Varshosaz J, Faghihian H, Rastgoo K, (2006) Preparation and characterization of metoprolol controlled-release solid dispersions. Drug Delivery 13: 295-302.
15. Szabo C, (2007) Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935.
16. Mishra PK, Tyagi N, Sen U, Givvimani S, Tyagi SC, (2010) H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol 298: H451-H456.
17. Wang XL, Wang Q, Guo W, Zhu YZ, (2011) Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection. Biosci Rep 31: 87-98.
18. Wang Q, Liu HR, Mu Q, Rose P, Zhu YZ, (2009) S-propargyl-cysteine Protects Both Adult Rat Hearts and Neonatal Cardiomyocytes From Ischemia/Hypoxia Injury: The Contribution of the Hydrogen Sulfide-Mediated Pathway. J Cardiovasc Pharmacol 54: 139-146.
19. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, et al. (1998) Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31: 1352-1356.
20. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, et al. (1998) Elevated levels of 8-iso-prostaglandin F-2 alpha in pericardial fluid of patients with heart failure- A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97: 1536-1539.
21. Dhalla AK, Hill MF, Singal PK, (1996) Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28: 506-514.
22. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, et al. (2002) Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34: 379-388.
23. Kimura Y, Kimura H (2004) Hydrogen sulfide protects neurons from oxidative stress. FASEB J 18: 1165-+.
24. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, et al. (2009) Hydrogen Sulfide Mediates Cardioprotection Through Nrf2 Signaling. Circ Res 105: 365-U105.
25. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, et al. (1996) Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182-1189.
26. Kang PM, Izumo S, (2000) Apoptosis and heart failure- A critical review of the literature. Circ Res 86: 1107-1113.
27. Yao LL, Huang XW, Wang YG, Cao YX, Zhang CC, et al. (2010) Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3 beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol 298: H1310-H1319.
28. Takano H, Zou YZ, Hasegawa H, Akazawa H, Nagai T, et al. (2003) Oxidative stress-induced signal transduction pathways in cardiac myocytes: Involvement of ROS in heart diseases. Antioxid Redox Signal 5: 789-794.